Ann Doherty
University of Edinburgh
20 Papers
58 Citations
Ann Doherty is an academic researcher from University of Edinburgh. The author has contributed to research in topics: Medicine & Cystic fibrosis transmembrane conductance regulator. The author has an hindex of 10, co-authored 15 publications. Previous affiliations of Ann Doherty include Western General Hospital & Free University of Berlin.
Chat about Author
Papers
Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: a randomised, double-blind, placebo-controlled, phase 2b trial
Eric W.F.W. Alton,David K Armstrong,Deborah Ashby,Katie J Bayfield,Diana Bilton,Emily V Bloomfield,A. Christopher Boyd,June Brand,Ruaridh Buchan,Roberto Calcedo,Paula Carvelli,Mario Chan,Seng H. Cheng,David Collie,Steve Cunningham,Heather E Davidson,Gwyneth Davies,Jane C. Davies,Lee A. Davies,Maria H Dewar,Ann Doherty,Jackie Donovan,Natalie S Dwyer,Hala I Elgmati,Rosanna F Featherstone,Jemyr Gavino,Sabrina Gea-Sorli,Duncan M. Geddes,James Sr Gibson,Deborah R. Gill,Andrew P. Greening,Uta Griesenbach,David M. Hansell,Katharine Harman,T Higgins,Samantha L Hodges,Stephen C. Hyde,Laura Hyndman,J. Alastair Innes,Joseph Jacob,Nancy Aaron Jones,Brian F Keogh,Maria P. Limberis,Paul Lloyd-Evans,Alan W Maclean,Michelle C Manvell,Dominique McCormick,Michael McGovern,Gerry McLachlan,C Meng,M Angeles Montero,Hazel Milligan,Laura J Moyce,Gordon D Murray,Andrew G. Nicholson,Tina Osadolor,Javier Parra-Leiton,David J. Porteous,Ian A. Pringle,Emma K Punch,Kamila M Pytel,Alexandra L. Quittner,Gina Rivellini,Clare Saunders,Ronald K. Scheule,Sarah Sheard,Nicholas J. Simmonds,Keith Smith,Stephen N. Smith,Najwa Soussi,Samia Soussi,Emma J Spearing,Barbara J Stevenson,Stephanie G Sumner-Jones,Minna Turkkila,Rosa P Ureta,Michael D Waller,Marguerite Y Wasowicz,James M. Wilson,Paul Wolstenholme-Hogg +79 more
TL;DR: In this article, a randomized, double-blind, placebo-controlled, phase 2b trial was conducted to assess the efficacy of non-viral CFTR gene therapy in patients with cystic fibrosis, where patients were randomly assigned to receive 5 mL of either nebulised pGM169/GL67A gene-liposome complex or 0·9% saline (placebo) every 28 days for 1 year.
410
Pre-clinical evaluation of three non-viral gene transfer agents for cystic fibrosis after aerosol delivery to the ovine lung.
Gerry McLachlan,Heather E Davidson,Emma Holder,Lee A. Davies,Ian A. Pringle,Stephanie G. Sumner-Jones,Alison Baker,Peter Tennant,Catherine Gordon,Christina Vrettou,R. Blundell,Laura Hyndman,Barbara J Stevenson,Abigail R. Wilson,Ann Doherty,Darren J. Shaw,Rebecca Coles,Hazel Painter,S H Cheng,Ronald K. Scheule,Jane C. Davies,J A Innes,S C Hyde,Uta Griesenbach,Eric W.F.W. Alton,A. C. Boyd,David J. Porteous,Deborah R. Gill,David Collie +28 more
TL;DR: The conclusion was that GL67A was the best non-viral GTA currently available for aerosol delivery to the sheep lung, led to the selection ofGL67A as the authors' lead GTA for clinical trials in CF patients.
108
A randomised, double-blind, placebo-controlled trial of repeated nebulisation of non-viral cystic fibrosis transmembrane conductance regulator ( CFTR) gene therapy in patients with cystic fibrosis
Eric W.F.W. Alton,David K Armstrong,Deborah Ashby,Katie J Bayfield,Diana Bilton,Emily V Bloomfield,A. Christopher Boyd,June Brand,Ruaridh Buchan,Roberto Calcedo,Paula Carvelli,Mario Chan,Seng H. Cheng,David Collie,Steve Cunningham,Heather E Davidson,Gwyneth Davies,Jane C. Davies,Lee A. Davies,Maria H Dewar,Ann Doherty,Jackie Donovan,Natalie S Dwyer,Hala I Elgmati,Rosanna F Featherstone,Jemyr Gavino,Sabrina Gea-Sorli,Duncan M. Geddes,James Sr Gibson,Deborah R. Gill,Andrew P. Greening,Uta Griesenbach,David M. Hansell,Katharine Harman,T Higgins,Samantha L Hodges,Stephen C. Hyde,Laura Hyndman,J. Alastair Innes,Joseph Jacob,Nancy Jones,Brian F Keogh,Maria P. Limberis,Paul Lloyd-Evans,Alan W Maclean,Michelle C Manvell,Dominique McCormick,Michael McGovern,Gerry McLachlan,C Meng,M Angeles Montero,Hazel Milligan,Laura J Moyce,Gordon D Murray,Andrew G. Nicholson,Tina Osadolor,Javier Parra-Leiton,David J. Porteous,Ian A. Pringle,Emma K Punch,Kamila M Pytel,Alexandra L. Quittner,Gina Rivellini,Clare Saunders,Ronald K. Scheule,Sarah Sheard,Nicholas J. Simmonds,Keith Smith,Stephen N. Smith,Najwa Soussi,Samia Soussi,Emma J Spearing,Barbara J Stevenson,Stephanie G Sumner-Jones,Minna Turkkila,Rosa P Ureta,Michael D Waller,Marguerite Y Wasowicz,James M. Wilson,Paul Wolstenholme-Hogg +79 more
- 22 Jul 2016
TL;DR: In this paper, a randomized, double-blind, placebo-controlled Phase IIb trial of the CFTR gene-liposome complex pGM169/GL67A was conducted to determine clinical efficacy of the formulation delivered to the airways over a period of 1 year in patients with CF.
Genomic sequence analysis of Fugu rubripes CFTR and flanking genes in a 60 kb region conserving synteny with 800 kb of human chromosome 7.
TL;DR: Overall sequence analysis suggests conservation of intron/exon boundaries between Fugu and human CFTR and revealed extensive homology between functional protein domains, however, the immediate 5' regions of human and Fugu CFTR are highly divergent with few conserved sequences apart from those resembling diminished cAMP response elements and CAAT box elements.
Limitations of the murine nose in the development of nonviral airway gene transfer
Uta Griesenbach,Stephanie G. Sumner-Jones,Emma Holder,Felix M. Munkonge,Theresa Wodehouse,Stephen N. Smith,Marguerite Y Wasowicz,Ian A. Pringle,Isabel Casamayor,Mario Chan,Rebecca Coles,Nikki Cornish,Ann Dewar,Ann Doherty,Raymond Farley,Anne-Marie Green,Bryony L. Jones,Mia D. B. Larsen,Anna E. Lawton,Michelle C Manvell,Hazel Painter,Charanjit Singh,Lucinda Somerton,Barbara J Stevenson,Anusha Varathalingam,Craig Siegel,Ronald K. Scheule,Seng H. Cheng,Jane C. Davies,David J. Porteous,Deborah R. Gill,A. Christopher Boyd,S C Hyde,Eric W.F.W. Alton +33 more
TL;DR: At the current levels of gene transfer efficiency achievable with nonviral vectors, the murine nose is of limited value as a stepping stone to human trials.
21